#significant difference versus baseline (P<.05).

Slides:

Advertisements

Similar presentations

UK Renal Registry 13th Annual Report Figure 12.1: Median height z-scores for transplant patients in 2009.

Advertisements

Copyright © 2010, 2007, 2004, 2000, Mosby, Inc., an affiliate of Elsevier Inc. All Rights Reserved. Focus on Dialysis and Kidney Transplant (Relates to.

AB 11 22 33 44 55 66 77 88 99 10  20  19  18  17  16  15  14  13  12  11  21  22  23  24  25  26  27  28.

Growth Hormone Treatment in Some Types of Skeletal Dysplasia and in Some Syndromes with Short Stature in KIGS Olcay Neyzi KIGS 10 Year Book, 1999.

UK Renal Registry 17th Annual Report Figure 9.1. Median height z-scores for transplant patients

Number of Dialysis and Transplant Units by Year, Number of Units Total Dialysis Only Transplant USRDS 1999 XI-1 Year.

UK Renal Registry 9 th Annual Report 2006 Fig 9.1 Percentage of patients with serum phosphate

UK Renal Registry 17th Annual Report Figure Percentage of patients waitlisted for a kidney transplant by renal centre, prior to or within two years.

GH Treatment in Children in Remission from Leukaemia and Lymphoma in KIGS Nikolaus Stahnke KIGS 10 Year Book, 1999.

Growth Hormone Treatment in Children with Malignant Cranial Tumours in KIGS Michael B Ranke and David A Price KIGS 10 Year Book, 1999.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Short Stature in Noonan Syndrome: Demography and Response to Growth Hormone Treatment in KIGS Barto J Otten KIGS 10 Year Book, 1999.

UK Renal Registry 16th Annual Report Figure Median height z-scores for transplant patients

Time Remaining 20:00.

Development of the KIGS Model for Predicting Growth Response to Growth Hormone Replacement Therapy in Children with Idiopathic Growth Hormone Deficiency.

Growth Hormone Treatment in Children with Intrauterine Growth Retardation and Silver-Russell Syndrome Pierre Chatelain KIGS 10 Year Book, 1999.

UK Renal Registry 15th Annual Report Figure 7.1. Median height z-scores for transplant patients

UK Renal Registry 9 th Annual Report 2006 Fig 14.1 Height Z scores for ERF patients aged 2 to 16 years in 2005.

Growth Hormone Treatment of Children with Prader-Willi Syndrome as Reported to KIGS: First-Year Growth Hormone E Martin Ritzén KIGS 10 Year Book, 1999.

Consultations can be made whilst you are viewing any area of the patient’s record SystmOne is Windows based, enabling users to perform the usual Windows.

Adverse Events - Demographics

Figure S1. A B C Survival probability (%) P = 0.21 P = 0.37 P = 0.12

0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().

Improved long-term graft function and similar height changes with very low-dose steroid versus late steroid withdrawal in pediatric renal transplantation.

ERT, estrogen replacement therapy

Volume 62, Issue 2, Pages (August 2002)

ANZDATA Registry 39th Annual Report Chapter 13: End Stage Kidney Disease in Aotearoa/New Zealand Data to 31-Dec-2015.

Figure 1. Serum B-ALP levels in normal male (•) and female (○) children as a function of age. Serum B-ALP levels were increased during infancy and puberty.

Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al.

CHAPTER 1 All Renal Replacement Therapy In Malaysia

GH peak (µg/l) Regression analysis of the GHRH+GHRP-6-elicited GH peaks plotted against body mass index (BMI), in 366 subjects with no endocrine pathology.

UK Renal Registry 13th Annual Report

Fig 6.1 Frequency of ischaemic heart disease in incident patients

Major physical anomalies according to parental origin of retained Xp

Atlas of Diseases of the Kidney

Effects of 5 yr of GH substitution in 118 GH-deficient adults on serum concentrations of TC, HDL-C, LDL-C and TG as well as on blood glucose, serum insulin.

Bones mass (BMC) and standing height in patients with COGHD compared with normal Russian adults. All values are compared with results obtained.

West Midlands Renal Peer Review

Atlas of Diseases of the Kidney

Relationship between karyotype and basal characteristics at GH start

Fig.1. The dose of GH administered to patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th.

A B GH and IGF-1 action on the effect of oral estrogen Pituitary Gland

Control Subjects MPHD Patients Control Subjects MPHD Patients

No GH (n=19) Treated with GH (n=67) Mean (SD) Range Mean (SD) Range

GH dose 12 months of treatment 24 months of treatment Low Medium High

Fig.1 Simple least-squares regression of the relationship between the log of peak GH concentration on standard GH stimulation tests and serum IGF-1 concentrations.

 Height SDS  Weight SDS

 Gruppe A: 0,033mg WH/kg x die  Gruppe B: 0,067mg WH/kg x die

Height velocity (cm/yr) Height velocity (cm/yr)

Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor

STAI: higher scores reflect more anxiety (scores 20-80).

Sensivity Sensivity Sensivity 100-specify 100-specify 100-specify

Comparison between groups

American Journal of Kidney Diseases

Romain Gallet et al. BTS 2016;1:14-28

Growth rate (cm/yr) Estrogen at age 12 Estrogen at age 15

Bigna M. Keller, Carmen Casaulta Aebischer, Richard Kraemer, Martin H

Abbildung mod. nach Van Pareren, 2004

Change in LBM (%)‏ LD CD LD CD LD CD

Volume 62, Issue 2, Pages (August 2002)

Chronic phenytoin increases activity levels in Mecp2Null/Y mice.

Massimo Meco, MD, Silvia Cirri, MD The Annals of Thoracic Surgery

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

Survival benefits of DAA in patients with decompensated cirrhosis

Fig. 4. The expression of TRAF6 in the PBMCs of the AR children after a 3-month SIT treatment. (A) Representative Western blot analysis of TRAF6 in the.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

UK Renal Registry 9th Annual Report 2006

Australia and New Zealand

Australia and New Zealand

Distribution of facility mean treatment time, by DOPPS region and phase. Distribution of facility mean treatment time, by DOPPS region and phase. Restricted.

Presentation transcript:

#significant difference versus baseline (P<.05). Height SDS Height Velocity (cm/year) Changes in height SDS and height velocity during GH treatment in cystinotic children receiving conservative treatment (CT) (A,B), receiving dialysis (D) (C,D) and after renal transplantation (Tx), (E,F). Patients receiving conservative treatment were subdivided into those who were treated for 1 year ((--) n=45), 2 years ((--) n=30), 3 years ((-- n=19), 4 years ((-- n=11), and 5 years ((-- n=8). Analysis for children receiving conservative treatment was restricted to patients who remained prepubertal during entire observation period. *significant difference versus previous year (P<.01). #significant difference versus baseline (P<.05). C D Height SDS Height Velocity (cm/year) E F Height SDS Height Velocity (cm/year) Abbildung mod. nach Wühl, 2001 rhGH treatment years rhGH treatment years